Recent Updates
Recently added Catalysts

BMS-986507

Phase 1

Lung Cancer | Small molecule | Oncology |Bristol-Myers Squibb Company|Last Updated: May 7, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment416
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06618287A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsPHASE1 RECRUITING 416 — — Feb 4, 2025Feb 26, 2031May 7, 202664 United States, Australia +7
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of participants with adverse events (AEs)
Up to 3 years
Number of participants with serious adverse events (SAEs)
Up to 3 years
Number of participants with AEs meeting protocol defined dose-limiting toxicity (DLT) critera
Up to 3 years
Number of participants with AEs leading to discontinuation
Up to 3 years
Number of participants with AEs leading to death
Up to 3 years
Number of DLTs that occur during the DLT evaluation period
Up to 3 weeks
Secondary Endpoints
Maximum observed serum concentration (Cmax)
Up to 3 years
Time of maximum observed concentration (Tmax)
Up to 3 years
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Up to 3 years
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Group AEXPERIMENTAL -
Group BEXPERIMENTAL -
Group CEXPERIMENTAL -
Group DEXPERIMENTAL -
Group EEXPERIMENTAL -
Interventions
NameTypeDescription
BMS-986507DRUGSpecified dose on specified days
OsimertinibDRUGSpecified dose on specified days
PembrolizumabDRUGSpecified dose on specified days
NivolumabDRUGSpecified dose on specified days
PumitamigDRUGSpecified dose on specified days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites64

Inclusion Criteria * Participants must have at least one measurable lesion per response evaluation criteria in solid tumors. * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participants must have a life expectancy of at least 3 months at the tim...

Countries:United StatesAustraliaCanadaChileFranceItalyNetherlandsSpainUnited Kingdom
Unlock Eligibility Criteria
Competitive Landscape -Lung Cancer 290 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK10PHASE3Pembrolizumab, Olaparib, Etoposide /m^2, Pembrolizumab/Vibostolimab Co-Formulation, Etoposide
Gilead Sciences, Inc.GILD5PHASE3Sacituzumab Govitecan, Topotecan, Amrubicin, Lurbinectedin, Domvanalimab
Amgen Inc.AMGN14PHASE3Tarlatamab, Durvalumab, ABP 234, Pembrolizumab, Lurbinectedin
AstraZeneca PLCAZN32PHASE3Durvalumab, Tremelimumab, Volrustomig, Pembrolizumab, Carboplatin
BioNTech SE Sponsored ADRBNTX6PHASE3Pumitamig, Atezolizumab, Etoposide, Carboplatin, PM8002
Bristol-Myers Squibb CompanyBMY15PHASE3MRTX849, Docetaxel, BMS-986489, Atezolizumab, Carboplatin
Pfizer Inc.PFE13PHASE3PF-08634404, Pembrolizumab, Chemotherapy Regimen 1, PF-07220060, Letrozole
AbbVie, Inc.ABBV4PHASE3ABBV-706, Topotecan, Lurbinectedin, Amrubicin, Telisotuzumab Adizutecan
ArriVent BioPharma, Inc.AVBP6PHASE3furmonertinib , daily, platinum-based chemotherapy, Firmonertinib, JAB-21822, Tislelizumab
Eli Lilly and CompanyLLY3PHASE3Ramucirumab, Erlotinib, Gefitinib, Osimertinib, LY4175408
Jazz Pharmaceuticals Public Limited CompanyJAZZ3PHASE3Atezolizumab, Lurbinectedin, Carboplatin, Etoposide, Durvalumab
Summit Therapeutics IncSMMT1PHASE3AK112
Revolution Medicines, Inc.RVMD2PHASE3daraxonrasib, docetaxel, RMC-6291, RMC-6236, Pembrolizumab
Incyte CorporationINCY3PHASE3Retifanlimab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK1PHASE3TAK-788, Pemetrexed, Cisplatin, Carboplatin
Regeneron Pharmaceuticals, Inc.REGN5PHASE2BNT116, Cemiplimab, Fianlimab, Pemetrexed, Paclitaxel
ImmunityBio IncIBRX3PHASE3Drug: Nogapendekin alfa inbakicept, Pembrolizumab, Cisplatin or Carboplatin, Nab-paclitaxel OR Pemetrexed, Nab-paclitaxel OR Paclitaxel OR Docetaxel
Immutep Ltd Sponsored ADRIMMP2PHASE3eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed, pembrolizumab, IMP321
GSK plc Sponsored ADRGSK1PHASE3Ris-Rez, Topotecan
Zai Lab Ltd. Sponsored ADRZLAB2PHASE3ZL-1310, Atezolizumab, Carboplatin
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06618287primaryCompletionDate: changed
LOWMay 24, 2026NCT06618287studyFirstPostDate: changed